RxDoctor Payments Data

Sean Lynch, DO

Family Medicine · Augusta, GANPI 1134142474

Payments from drug & device makers

$32,568in general payments, 2019–2025

Across 632 payments — averaging $51.53 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk AS$23K
  • Novo Nordisk$2K
  • AbbVie$1K
  • GSK$922
  • Pfizer$697
  • Lilly USA, LLC$666
  • plus $4K from 38 others

What the payments were for

  • Travel & lodging$3213%
  • Food & beverage$9,30696%
  • Education$511%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$32,568 in reported general payments places this provider in the 95th percentile of 3,111 family medicine providers in Georgia.

See all family medicine providers in Georgia

Medicare billing

Part B allowed, 2024
$135,212
Medicare patients
329
Services billed
2,293

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide132$152,698
EliquisApixaban251$133,335
JanuviaSitagliptin Phosphate169$115,256
Trelegy ElliptaFluticasone/Umeclidin/Vilanter77$78,802
JardianceEmpagliflozin72$74,164
XareltoRivaroxaban51$44,866
ShingrixVaricella-Zoster Ge/As01b/Pf148$33,239
TrulicityDulaglutide24$32,262
FarxigaDapagliflozin Propanediol28$31,794
RybelsusSemaglutide26$28,666
Combivent RespimatIpratropium/Albuterol Sulfate26$19,510
GlatopaGlatiramer Acetate11$15,967
MyrbetriqMirabegron22$12,451
Spiriva HandihalerTiotropium Bromide11$11,868
Tresiba Flextouch U-100Insulin Degludec15$10,337

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$2,361$181,363158 claims
PfizerEliquis$697$133,335251 claims
GSKTrelegy Ellipta, Shingrix, Breo Ellipta, Arexvy$922$126,674258 claims
MerckJanuvia, Janumet Xr$56$124,758184 claims
Boehringer IngelheimJardiance, Combivent Respimat$287$93,67498 claims
AstraZenecaFarxiga, Symbicort$498$36,78942 claims
Lilly USA, LLCTrulicity$666$32,26224 claims
Astellas Pharma US IncMyrbetriq$132$12,45122 claims
AbbVieSynthroid$1,005$2,21927 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 3,111 family medicine providers in Georgia.

Other family medicine in Augusta

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →